S**upplementary Table S5.** Treatment-Related Adverse Events

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| AEs *n (%)* | 　 | Anlotinib | Immunotherapy | A+P combination therapy | c2 | *P* |
| General condition | 　 | 　 | 　 | 　 | 　 | 　 |
| 　 | Fatigue | 53 (37.3%) | 20 | 12 | 21 | 0.272  | 0.873  |
| 　 | Anorexia symptoms  | 45 (31.7%) | 20 | 9 | 16 | 0.770  | 0.681  |
| 　 | Headache/Dizziness | 47 (33.1%) | 17 | 12 | 18 | 1.148  | 0.563  |
| 　 | Neutropenia | 34 (23.9%) | 14 | 5 | 15 | 0.926  | 0.629  |
| Gastrointestinal system | 　 | 　 | 　 | 　 | 　 | 　 |
| 　 | Diarrhea  | 15 (10.6%) | 7 | 4 | 4 | 1.301  | 0.522  |
| 　 | Oral mucositis  | 13 (9.2%) | 7 | 3 | 3 | 1.841  | 0.398  |
| 　 | Vomiting  | 11 (7.7%) | 8 | 1 | 2 | 5.533  | 0.063  |
| Hepatobiliary system | 　 | 　 | 　 | 　 | 　 | 　 |
| 　 | Transaminitis | 30 (21.1%) | 9 | 4 | 17 | 4.383  | 0.112  |
| Respiratory system | 　 | 　 | 　 | 　 | 　 | 　 |
| 　 | Cough | 28 (19.7%) | 12 | 7 | 9 | 1.017  | 0.601  |
| 　 | Dyspnea | 5 (3.5%) | 2 | 1 | 2 | 0.001  | 1.000  |
| 　 | Hemoptysis  | 9 (6.3%) | 3 | 3 | 3 | 0.986  | 0.611  |
| Cardiovascular system | 　 | 　 | 　 | 　 | 　 | 　 |
| 　 | Hypertension  | 27 (19.0%) | 8 | 6 | 13 | 1.398  | 0.497  |
| Skin system | 　 | 　 | 　 | 　 | 　 | 　 |
| 　 | Rash | 21 (14.8%) | 10 | 4 | 7 | 0.726  | 0.696  |
| 　 | Hand-foot syndrome | 18 (12.7%) | 8 | 5 | 5 | 1.462  | 0.481  |
| 　 | Pruritus | 25 (17.6%) | 11 | 6 | 8 | 0.851  | 0.653  |
| *AEs, adverse events* | 　 | 　 | 　 | 　 | 　 | 　 |